Charles G. Mullighan

Blood Cancer Discovery, Scientific Editor

Charles G. Mullighan, MBBS (Hons), MSc, MD, is the Deputy Director of the St. Jude Children’s Research Comprehensive Cancer Center. He joined the St. Jude Department of Pathology in 2008 and currently serves as co-leader of the Cancer Center’s Hematological Malignancies Program.

Dr. Mullighan’s research focuses on defining the landscape of genomic and epigenomic alterations that drive the pathogenesis of acute lymphoblastic leukemia (ALL) and related disorders and then using this information to develop experimental models that faithfully recapitulate the genetics of human ALL. He has led landmark studies that have profoundly influenced our understanding of genetic basis of ALL and have led to novel diagnostic and therapeutic approaches and multiple clinical trials. In 2018, Dr. Mullighan established the Public Resource of Patient-derived and Expanded Leukemias, or PROPEL, initiative. This initiative makes available to the scientific community one of the world’s largest collections of clinically and genetically characterized xenograft leukemia samples from children and adults.

Dr. Mullighan has been an active member of the American Association for Cancer Research (AACR) since 2004 and is currently serving as a Scientific Editor for Blood Cancer Discovery. He has received numerous honors, including the National Cancer Institute R35 Outstanding Investigator Award (2017) and the American Association for Cancer Research Team Science Award (2009).

• Mutational Landscape and Patterns of Clonal Evolution in Relapsed Pediatric Acute Lymphoblastic Leukemia
  Waanders E…Mullighan CG. Blood Cancer Discovery January 2020.
• Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma
  Wei X…Chen S. Cancer Research May 2018.
• Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia
  Diaz-Flores E…Kim KL. Cancer Research May 2019.
• Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia
  Kannan S…Shelley M. Molecular Cancer Therapeutics September 2019.
• OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL
  Evans K…Pritchard T. Clinical Cancer Research July 2019.